Intralesional rhEGF (Heberprot-P related)

About Discovery Therapeutics Caribe

Discovery Therapeutics Caribe is a private, late-stage biotech firm founded in 2015, targeting the significant unmet medical need in diabetic foot ulcer (DFU) care. The company's core asset is based on intralesional recombinant human Epidermal Growth Factor (rhEGF), a biologic approach designed to stimulate healing in complex wounds. Operating from San Juan, the company positions itself with global partners and is focused on navigating the clinical and regulatory pathway to bring this therapy to the American market. Its activities suggest a strategic effort to localize and develop an existing biologic candidate for a new, high-value geographic region.

Therapeutic Areas

Other Diabetic Foot Ulcers (DFU) Drugs